Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer

OBJECTIVE: The TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option. The aim of this study was to assess the cost effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Zhuo-miao, Xu, Zhe, Li, Huan, Li, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950513/
https://www.ncbi.nlm.nih.gov/pubmed/36844853
http://dx.doi.org/10.3389/fpubh.2023.1046424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950513/
https://www.ncbi.nlm.nih.gov/pubmed/36844853
http://dx.doi.org/10.3389/fpubh.2023.1046424

Ejemplares similares